Skip to content

Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

LCS® PS: A Prospective, Multi-center Clinical Investigation of the LCS® Complete Posterior Stabilized Mobile-bearing Total Knee System

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00487565
Enrollment
210
Registered
2007-06-18
Start date
2006-09-30
Completion date
2011-02-28
Last updated
2013-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Arthritis, Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis

Keywords

Total knee replacement, Total knee arthroplasty, Osteoarthritis, Rheumatoid or other inflammatory arthritis, Post-traumatic or juvenile arthritis

Brief summary

Prospective, multi-center clinical study to evaluate the clinical outcomes of the posterior stabilized design of the LCS® Complete Mobile-bearing Total Knee System

Detailed description

Prospective, multi-center study to evaluate the clinical outcome of posterior stabilized design of LCS® Complete Mobile-Bearing Total Knee System. No comparison group. 12 month enrollment, 12 month post-operative evaluation. Follow-up intervals: Pre-op, 3 month, 6 month, and 12 month.

Interventions

DEVICETotal knee arthroplasty

Total knee arthroplasty using a posterior stabilized implant

Sponsors

DePuy Orthopaedics
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* M/F * 18-80 * Diagnosis of osteoarthritis, rheumatoid , post-traumatic, inflammatory, juvenile arthritis. * Skeletally mature, sufficient bone stock to seat and support prosthesis * Willing/able return for follow-up. * Subject is willing and able to provide informed patient consent for participation in the study

Exclusion criteria

* History of recent/active joint sepsis, charcot neuropathy, psycho-social disorders, prior knee arthroplasty on affected site, metabolic disorders of calcified tissue * Communicable diseases that may limit follow-up * Medical-legal or workers compensation claims.

Design outcomes

Primary

MeasureTime frameDescription
Knee Active Flexion12 monthActive flexion is measured by how much a patient can bend their knee on their own, without assistance.

Countries

United States

Participant flow

Recruitment details

Between September 2006 and February 2011, 210 subjects were recruited and enrolled at 4 clinics by orthopaedic surgeons. Recruitment was based on the inclusion and exclusion criteria in the clinical investigation plan.

Pre-assignment details

This was a non-randomized study so all subjects that met the inclusion/exclusion criteria received the LCS Complete Posterior Stabilized implant. Consented subjects could be excluded from the trial based on results of pre-operative clinical and/or radiographic evaluations, as per the exclusion criteria in the clinical investigation plan.

Participants by arm

ArmCount
LCS Complete Posterior Stabilized Knee Implant
Total knee arthroplasty with a posterior stabilized implant
210
Total210

Baseline characteristics

CharacteristicLCS Complete Posterior Stabilized Knee Implant
Age Continuous
Age
63.8 participants
STANDARD_DEVIATION 9.8
Region of Enrollment
Switzerland
30 participants
Region of Enrollment
United States
180 participants
Sex: Female, Male
Female
120 Participants
Sex: Female, Male
Male
90 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
11 / 210
serious
Total, serious adverse events
28 / 210

Outcome results

Primary

Knee Active Flexion

Active flexion is measured by how much a patient can bend their knee on their own, without assistance.

Time frame: 12 month

ArmMeasureValue (MEAN)Dispersion
LCS Complete Posterior Stabilized Knee ImplantKnee Active Flexion119.2 degreesStandard Deviation 9.9

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026